Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NX-5948 assigned the nonproprietary name “bexobrutideg”
U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia
Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with Sanofi
Enhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officer
Well capitalized with cash and marketable securities of $549.7 million

Read more at globenewswire.com